CRM funds research on a competitive basis by employing independent expert peer reviews of our research programs every 3 – 5 years.

This system is regarded as an international benchmark of excellence, and provides a guarantee on the quality of our research. In peer reviews, proposals for funding are considered and assessed for scientific quality by a number of senior academics, or "peers", from Malaysia and overseas, who work within relevant areas of research, which provides the basis of the funding decision.

Once decided, our Scientific Advisory Board reviews the scientific, and provides recommendations to the Board of Trustees. The SAC also provides advice to the Board and the Chief Executive on the scope and focus of cancer research areas, with the most appropriate areas for research investment.
PROFESSOR ADRIAN HARRIS

PROFESSOR ADRIAN HARRIS

Adrian L Harris is the Cancer Research UK Professor of Medical Oncology at the University of Oxford, and directs the Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine (WIMM). He is a Consultant Medical Oncologist, a Professorial Fellow of St Hugh’s College Oxford, the Chairman of the CRUK Oxford Cancer Centre, and joint lead of the Cancer theme of the Comprehensive Biomedical Research Centre in Oxford. He is also Editor-in-Chief of the British Journal of Cancer and on the Editorial Board of Cancer Cell, being a Senior Investigator in the National Institute of Health Research and a Fellow of the Academy of Medical Sciences.
Read More
He is a ‘Highly Cited Researcher 2014’ ranking among the top 1% most cited for their subject field and year of publication—between 2002 and 2012 and included in Thomson Reuters’ ‘2014 World’s most Influential Scientific Minds.’ He has published over 1000 papers with over 105,000 citations to them, and has been receiving a Platinum Merit Award from the National Health Service for the last 15 years, given to the 200 most outstanding consultants in any speciality.
Prof. Harris trained in Medicine and Biochemistry at Liverpool University, obtained a DPhil at Oxford University, and trained at the Royal Marsden Hospital in Medical Oncology. He was appointed Professor of Clinical Oncology at Newcastle-upon-Tyne in 1982. He has been the Professor of Medical Oncology at Oxford University since 1988. He directs the Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine, and has been managing breast cancer patients for over 30 years.
His major laboratory interests involve the role of hypoxia in breast tumour biology and tumour angiogenesis, the metabolic response to hypoxia, microRNAs induced by hypoxia and hypoxia-induced cell death. He has conducted many predictive and prognostic studies and early exploratory phase trials in new drug development and molecular pathology to translate laboratory findings to clinical relevance and development of new agents.
In the Department of Oncology, over 20 Phase I and II trials have been run, and current trials include new drugs blocking angiogenesis, metabolism inhibitors, DNA repair, immunotherapy, inhibitors of signal transduction and their interactions with radiotherapy. Specific emphasis is on classification of tumours by functional imaging, molecular profiles, and pharmacodynamic endpoints to targeted therapies.
PROFESSOR PAUL PHAROAH

PROFESSOR PAUL PHAROAH

Professor Paul Pharoah is a professor of cancer epidemiology at the Centre for Cancer Genetic Epidemiology at the University of Cambridge.
Read More
As a medical doctor with training in public health, Professor Pharoah’s research group has led in studies to uncover the genetic basis of ovarian cancer. He is a leading researcher in the international Ovarian Cancer Genetic study.
PROFESSOR PATRICK TAN

PROFESSOR PATRICK TAN

Dr. Patrick Tan is a Professor at the Duke-NUS Medical School and Deputy Executive Director of the Biomedical Research Council (Agency for Science, Technology, and Research). He directs PRISM, the SingHealth DukeNUS Institute of Precision Medicine, and was the Program Director of POLARIS, which established the first CAP-certified facilities for next-generation sequencing and the first clinically implemented NGS panel in South East Asia.
Read More
He is an elected member of the American Society for Clinical Investigation (ASCI), the Bioethics Advisory Committee (BAC), a national body that provides advice to the Singapore government on ethical issues related to biomedical research, a Board Member of the International Gastric Cancer Association, and a Member of the AACR International Affairs Committee. He co-leads the biliary tract cancer project of the International Cancer Genome Consortium (ICGC), and is co-chair of the Singapore National Precision Medicine Program Steering Committee.

He received his B.A. (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he received the Charles Yanofsky prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. Other awards include the President’s Scholarship, Loke Cheng Kim scholarship, Young Scientist Award (A-STAR), Singapore Youth Award (twice), SingHealth Investigator Excellence Award, Chen New Investigator Award (Human Genome Organization), President’s Science Award, and the Japanese Cancer Association International Award.

Professor Jeff Dunn

Professor Jeff Dunn

Professor Jeff Dunn is the Research Leader of Social and Behavioural Science within Cancer Council Queensland’s Cancer Research Centre as well as Professor and Chair of Transformative Social Science, a prestigious appointment at the University of Southern Queensland.
Read More
As the CEO of CCQ for more than 15 years and as a Board member of the International Union Against Cancer (UICC), Jeff has considerable expertise in the behavioural and social scientific aspects of cancer control and an impressive track record in research leadership across the continuum of prevention, early detection, supportive care and quality of life.
Professor Hany Ariffin

Professor Hany Ariffin

Dr. Hany is a professor and senior consultant paediatric oncologist at the University of Malaya Medical Centre, and was the Director of the University Malaya Cancer Research Institute.
Read More
She served as the President of Malaysian Society of Paediatric Haematology-Oncology in 2011, and has an active track record in improving the survival of children with cancer.
Mr Wong Lup Hang

Mr Wong Lup Hang

Mr. Wong has extensive senior leadership experience in dealing with multinationals in Malaysia and abroad.
Read More
Having grieved the loss of a much loved daughter to cancer, Mr Wong puts a human face on the need for cancer research, and brings a different perspective to the Scientific Advisory Committee, ensuring that the research remains patient-focused.